Loading…
Loading…
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Athena Investment Management lessened its stake in Eli Lilly and Company (NYSE: LLY) by 35.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 831 shares of the company's stock after selling 450 shares during the quarter. Athena Investment Management's holdings in Eli Lilly and
Burford Brothers Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 890 shares of the company's stock, valued at approximately $1,068,000. A number of
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Griffin's Citadel Advisors and Druckenmiller's Duquesne Family Office bought Lilly stock in Q2. The billionaires likely capitalized on an opportunity with Lilly's shares tumbling early in the quarter.
Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.